Imunon, Inc.
CLSN
Rank in Stocks
#34869
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Share Price
$1.96
Last synced: 2022-09-20
Market Cap
$4.46M
Change (1 day)
0.00%
Change (1 year)
122.70%
Country
US
Trade Imunon, Inc. (CLSN)
Category
Healthcare
Stock price history for Imunon, Inc. (CLSN)
Highest end of day price: $0.93 on 2025-01-01
Lowest end of day price: $37.95 on 2018-01-01
Lowest end of day price: $37.95 on 2018-01-01
Stock price history of Imunon, Inc. from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2025 | 10.76% |
| 2024 | -3.79% |
| 2023 | -36.24% |
| 2022 | -86.26% |
| 2021 | -10.52% |
| 2020 | -70.48% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
